Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2021 07:00 ET | Source: Clene Inc.

Clene Reports First Quarter 2021 Operating and Financial Highlights

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients ...
April 30, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Technology

SALT LAKE CITY, April 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
March 29, 2021 07:00 ET | Source: Clene Inc.

Clene Reports Full Year 2020 Operating and Financial Highlights

Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics Topline data from a Phase 2 ALS trial and two Phase 2 target engagement studies in MS and Parkinson’s...
March 10, 2021 09:00 ET | Source: Clene Inc.

Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference and Launch of Clene Spotlight Webpage on M Vest LLC

SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
March 09, 2021 08:32 ET | Source: Clene Inc.

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

SALT LAKE CITY, March 09, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
March 03, 2021 16:05 ET | Source: Clene Inc.

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a...
March 01, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine Awarded Michael J. Fox Foundation Grant to Accelerate the Development of CNM-Au8 as a Treatment for Parkinson’s Disease

Interim data from a Phase 2 target engagement study show that CNM-Au8 treatment was associated with improvements across key CNS bioenergetic metabolites in Parkinson’s disease patients Initiation of a...
February 25, 2021 07:31 ET | Source: Clene Inc.

Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

Blinded interim data from VISIONARY-MS continue to support the potential of CNM-Au8 to drive meaningful neurological functional improvements in MS patientsInterim REPAIR-MS results provide further...
February 19, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021

SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
February 16, 2021 07:00 ET | Source: Clene Inc.

Clene Nanomedicine Initiates Phase 2 Study of CNM-ZnAg for Patients with COVID-19

Study to evaluate CNM-ZnAg in acutely symptomatic, non-hospitalized COVID-19 patients SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries,...